| Outcome Measures: |
Primary: Number of Participants Who Experienced at Least One Adverse Event (AE), An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2., Up to 14 days after last dose of study drug|Number of Participants Who Discontinued Study Drug Due to an AE, An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2., Up to 14 days after last dose of study drug | Secondary: Plasma Pharmacokinetic Parameter: Area Under the Concentration-time Curve (AUC)(0-24hr) of MK-0941, Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period., Up to 72 hours after study drug administration|Plasma Pharmacokinetic Parameter: Maximum Concentration (Cmax) of MK-0941, Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period., Up to 72 hours after study drug administration|Plasma Pharmacokinetic Parameter: Time to Reach Cmax (Tmax) of MK-0941, Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period., Up to 72 hours after study drug administration|Plasma Pharmacokinetic Parameter: Concentration of MK-0941 at 24 Hours (C24hr), Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period., Up to 72 hours after study drug administration|Plasma Pharmacokinetic Parameter: Apparent Terminal Elimination Half-life (t1/2) of MK-0941, Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period., Up to 72 hours after study drug administration|Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr, Geometric Mean of the Day 5 to Day 1 Accumulation Ratio, Day 5 and Day 1
|
